Tuesday, March 13, 2007

VentiRx Licenses Technology From Array BioPharma

VentiRx Pharmaceuticals, which conducts operations in Seattle, announced today with Array BioPharma that the firm has license Array's Toll-like receptor (TLR) program. Financial terms of the deal were not announced. The firms said that Array will receive equity in VentiRx plus milestone payments and royalties as part of the deal. VentiRx said the first two candidates from the program are expected to be in the oncology and allergy areas.